Cargando…
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
Although clinical trials and real-world studies have affirmed the effectiveness and safety of the FDA-authorized COVID-19 vaccines, reports of breakthrough infections and persistent emergence of new variants highlight the need to vigilantly monitor the effectiveness of these vaccines. Here we compar...
Autores principales: | Puranik, Arjun, Lenehan, Patrick J., Silvert, Eli, Niesen, Michiel J.M., Corchado-Garcia, Juan, O’Horo, John C., Virk, Abinash, Swift, Melanie D., Halamka, John, Badley, Andrew D., Venkatakrishnan, A.J., Soundararajan, Venky |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366801/ https://www.ncbi.nlm.nih.gov/pubmed/34401884 http://dx.doi.org/10.1101/2021.08.06.21261707 |
Ejemplares similares
-
FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system
por: Pawlowski, Colin, et al.
Publicado: (2021) -
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
por: Puranik, Arjun, et al.
Publicado: (2022) -
Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records
por: Niesen, Michiel J. M., et al.
Publicado: (2022) -
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
por: Puranik, Arjun, et al.
Publicado: (2022) -
Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection
por: Niesen, Michiel J M, et al.
Publicado: (2022)